ClinicalTrials.gg
CompletedNCT00102687Updated Nov 22, 2019Results posted

Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

A Phase 2 interventional study of azacitidine in Myelodysplastic Syndromes, sponsored by Celgene. Completed at 31 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-22.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
12th of 126
151 · median 38
Started
2005
with 6 others
Phase 2
63 of 130
5 open now
Registered
5th of 130
by date
Lead sponsor
14 of 130
Celgene

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 12th largest by enrollment of the 126 interventional ones that give a count, is one of 7 that started in 2005, is one of 63 in phase 2, and was the 5th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of this study is to determine if azacitidine, combined with Best Supportive Care (BSC), is effective in treating myelodysplastic syndromes (MDS) when given according to a different doses and dosing schedules.

Read the detailed description

Comparison/Control Interventions: The comparison is azacitidine at different doses and schedules.

Duration of Intervention: Treatment lasted for a maximum of 18 cycles, which is up to 24 months.

03

Conditions studied

  • Myelodysplastic Syndromes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of anemia, refractory anemia with ringed sideroblasts and at least one of the following: a)Anemia with \<110g/L and requires at least 1 unit packed red blood cell transfusions every 28 days; b)Thrombocytopenia with counts \<100 x 10\^9/L; or c)Neutropenia with \<1.5 x 10\^9/L.
  • OR, Refractory anemia with excess blasts or refractory anemia with excess blast in transformation, according to the French-American-British classification system for MDS.
  • At least 18 years of age.
  • Have a of >7 months.
  • Unlikely to proceed to bone marrow or stem cell transplantation therapy following remission.
  • Have serum levels less than or equal to 1.5 times the (ULN) range for the laboratory.
  • Have serum glutamic-oxaloacetic transaminase () or serum glutamic-pyruvic transaminase (alanine aminotransferase) levels less than or equal to 2 x ULN.
  • Have serum creatinine levels less than or equal to 1.5 x ULN.

Exclusion criteria

Exclusion Criteria:

  • Secondary MDS.
  • Prior treatment with azacitidine.
  • Any prior history of Acute Myeloid Leukemia (AML).
  • Malignant or disease within the previous 12 months.
  • Uncorrected red cell folate deficiency or vitamin B12 deficiency.
  • Hepatic tumors.
  • Radiation, chemotherapy, or cytotoxic therapy for non-MDS conditions in the previous 12 months.
  • Known or suspected to azacitidine or mannitol.
  • Prior transplantation or cytotoxic therapy to treat MDS. Prior use of Revlimid and Thalomid allowed after 30 day washout.
  • Serious medical illness likely to limit survival to less than or equal to 7 months.
  • Treatment with androgenic hormones during the previous 14 days
  • Active viral infection with known or vial hepatitis Type B or C.
  • Treatment with other drugs with the previous 30 days.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Aza-5

    Azacitidine administered subcutaneously at 75mg/m\^2 for 5 days on a 28 day cycle.

    Drug: azacitidine

  • Experimental
    Aza-5-2-2

    Azacitidine administered subcutaneously at 75mg/m\^2 for 5days with 2 days off, then for an additional 2 days, on a 28 day cycle.

    Drug: azacitidine

  • Experimental
    Aza-5-2-5

    Azacitidine administered subcutaneously at 50mg/m\^2 for 5 days with 2 days off, then for an additional 5 days, on a 28 day cycle.

    Drug: azacitidine

  • Experimental
    Maintenance Aza 5 days q 4 weeks

    Azacitidine administered subcutaneously at 75mg/m\^2 for 5 days every 4 weeks.

    Drug: azacitidine

  • Experimental
    Maintenance Aza 5 days q 6 weeks

    Azacitidine administered subcutaneously at 75mg/m\^2 for 5 days every 6 weeks.

    Drug: azacitidine

Interventions

  • Azacitidine is administered subcutaneously Total of 18 cycles on treatment or early discontinuation.

06

What researchers measure

Primary outcomes

  1. Number of Participants In Best Hematological Response Categories as Determined by the Investigator Using International Working Group 2000 (IWG 2000) Criteria For Myelodysplastic Syndromes (MDS) During the Initial Study Period.

    Participant counts by best hematological response; complete remission(CR) is better than a partial remission(PR) which is better than stable disease(SD). Investigator determined responses followed IWG 2000 criteria for MDS CR: repeat bone marrow show \<5% myeloblasts, and peripheral blood evaluations lasting \>=2 months of hemoglobin(\>110 g/L), neutrophils(\>=1.5x10\^9/L), platelets(\>=100x10\^9/L), blasts (0%) and no dysplasia PR is the same as CR for peripheral blood: bone marrow shows blasts decrease by \>=50% or a less advanced FAB classification from pretreatment (see Population Descrip)

    Time frame: Day 1 (randomization) to 6 months

  2. Number of Participants With Best Hematological Improvement Derived Using International Working Group 2000 (IWG 2000) Criteria for MDS During the Initial Study Period.

    IWG 2000 Criteria: Pretreatment=hemoglobin \<110g/L or RBC transfusion-dependence, platelet count \<100x10\^9/L or platelet transfusion dependence, absolute neutrophil count \<1.5x10\^9/L. Erythroid response: Major-\>20g/L increase in hemoglobin or transfusion independence. Minor- 10-20g/L increase in hemoglobin or \>=50% decrease in transfusion requirements. Platelet response: Major-absolute increase of platelet count by \>=30x10\^9/L or platelet transfusion independence. Minor-\>=50% increase in platelet count with net increase \>10x10\^9/L but \<30x10\^9/L. (continued in Population Description)

    Time frame: Day 1 (randomization) to 6 months

  3. Number of Participants With Overall Best Hematologic Response and Hematologic Improvement Based on IWG 2000 Criteria For MDS During the Initial Study Period

    Number of participants whose best hematological outcome was either complete remission (CR), partial remission (PR) (as determined by the investigator), or any hematologic improvement (based on the IWG 2000 criteria for MDS). See previous outcomes for detailed definitions.

    Time frame: Day 1 (randomization) to 6 months

  4. Number of Participants Who Improved or Maintained The Hematologic Response From the Initial Study Period (Based on IWG 2000 Criteria For MDS) During the Maintenance Period

    Hematologic response during the maintenance period are compared to the response in the initial study period. Initial response could have been a complete remission, a partial remission, stable disease or a hematologic improvement. Maintenance period best response is after randomization to a maintenance arm for those randomized, and is after the start of cycle 7 for those remaining on initial period treatment throughout the study.

    Time frame: 24 months

Secondary outcomes

  1. Baseline Hemoglobin Values

    The median values for hemoglobin based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for hemoglobin. Baseline values are used to compare to values following treatment.

    Time frame: Day 1 (randomization)

  2. Change From Baseline in Hemoglobin at End of Initial Study Period (6 Months)

    The difference between hemoglobin values at the end of the initial study period minus the hemoglobin values at baseline.

    Time frame: 6 months

  3. Change From Baseline in Hemoglobin at the End of the Maintenance Study Period

    The difference between hemoglobin values at the end of the maintenance study period minus the hemoglobin values at baseline.

    Time frame: 24 months

  4. Baseline Platelet Values

    The median values for platelets based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for platelets. Baseline values are used to compare to values following treatment.

    Time frame: Day 1 (randomization)

  5. Change From Baseline in Platelets at the End of Initial Study Period (6 Months)

    The difference between platelet values at the end of the initial study period minus the platelet values at baseline.

    Time frame: 6 months

  6. Change From Baseline in Platelets at the End of the Maintenance Study Period (Month 24)

    The difference between platelet values at the end of the maintenance study period minus the platelet values at baseline.

    Time frame: 24 months

  7. Baseline Absolute Neutrophil Count (ANC) Values

    The median values for ANC based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for ANC. Baseline values are used to compare to values following treatment.

    Time frame: Day 1 (randomization)

  8. Change From Baseline in Absolute Neutrophil Count (ANC) at the End of Initial Study Period (6 Months)

    The difference between ANC values at the end of the initial study period minus the ANC values at baseline.

    Time frame: 6 months

  9. Change From Baseline in Absolute Neutrophil Count (ANC) at the End of the Maintenance Study Period (Month 24)

    The difference between ANC values at the end of the maintenance study period minus the ANC values at baseline.

    Time frame: 24 months

  10. Red Blood Cell (RBC) Transfusion Status at Baseline and End of Initial Study Period (6 Months)

    Shift table comparing the RBC transfusion status of patients at the end of the initial study period to the transfusion status at baseline.

    Time frame: 6 months

  11. Platelet Transfusion Status at Baseline and End of Initial Study Period (6 Months)

    Shift table comparing the platelet transfusion status of patients at the end of the initial study period to the transfusion status at baseline.

    Time frame: 6 months

  12. Red Blood Cell (RBC) Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)

    Shift table comparing the RBC transfusion status of patients at the end of the maintenance study period to the transfusion status at baseline.

    Time frame: 24 months

  13. Platelet Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)

    Shift table comparing the platelet transfusion status of patients at the end of the maintenance study period to the transfusion status at baseline.

    Time frame: 24 months

  14. Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Initial Study Period

    Baseline uses the average number of infections requiring IV antibiotic treatment from the 28 days prior to and including the day of first dose to an initial treatment arm. Initial study period values total the number of infections requiring IV antibiotic treatment divided by the number of treatment cycles (each cycle is approximately one month).

    Time frame: 6 months

  15. Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Maintenance Study Period

    Baseline uses the average number of infections requiring IV antibiotic treatment from the 28 days prior to and including the day of first dose to an initial treatment arm. Maintenance study period values total the number of infections requiring IV antibiotic treatment divided by the number of treatment cycles (each cycle is approximately one month).

    Time frame: 24 months

07

Results

Posted May 28, 2010

Participant flow

Initial Period
Participant flow — Initial Period
MilestoneAza-5Aza-5-2-2Aza-5-2-5Maintenance Aza 5 Days q 4 WeeksMaintenance Aza 5 Days q 6 Weeks
Started50505100
Completed32222500
Not completed18282600
Withdrew: Withdrawal by subject63500
Withdrew: Adverse event47900
Withdrew: Transformation to aml (blast > 30%)13000
Withdrew: Protocol violation00200
Withdrew: Physician decision29600
Withdrew: Sponsor's decision01100
Withdrew: Failed treatments (relapse,disease prog)44200
Withdrew: Death11100
Maintenance Period
Participant flow — Maintenance Period
MilestoneAza-5Aza-5-2-2Aza-5-2-5Maintenance Aza 5 Days q 4 WeeksMaintenance Aza 5 Days q 6 Weeks
Started13682221
Completed622128
Not completed7461013
Withdrew: Withdrawal by subject40231
Withdrew: Adverse event10013
Withdrew: Transformation to aml (blast > 30%)01020
Withdrew: Failed treatment (relapse,disease prog)11134
Withdrew: Death00011
Withdrew: Physician decision12304

Outcome measures

PrimaryNumber of Participants In Best Hematological Response Categories as Determined by the Investigator Using International Working Group 2000 (IWG 2000) Criteria For Myelodysplastic Syndromes (MDS) During the Initial Study Period.

Participant counts by best hematological response; complete remission(CR) is better than a partial remission(PR) which is better than stable disease(SD). Investigator determined responses followed IWG 2000 criteria for MDS CR: repeat bone marrow show \<5% myeloblasts, and peripheral blood evaluations lasting \>=2 months of hemoglobin(\>110 g/L), neutrophils(\>=1.5x10\^9/L), platelets(\>=100x10\^9/L), blasts (0%) and no dysplasia PR is the same as CR for peripheral blood: bone marrow shows blasts decrease by \>=50% or a less advanced FAB classification from pretreatment (see Population Descrip)

Time frame:
Day 1 (randomization) to 6 months
Reported as:
Number · participants
Number of Participants In Best Hematological Response Categories as Determined by the Investigator Using International Working Group 2000 (IWG 2000) Criteria For Myelodysplastic Syndromes (MDS) During the Initial Study Period.
participantsAza-5Aza-5-2-2Aza-5-2-5
Overall Response (CR+PR)434
Complete remission (CR)222
Partial remission (PR)212
Stable disease221920
PrimaryNumber of Participants With Best Hematological Improvement Derived Using International Working Group 2000 (IWG 2000) Criteria for MDS During the Initial Study Period.

IWG 2000 Criteria: Pretreatment=hemoglobin \<110g/L or RBC transfusion-dependence, platelet count \<100x10\^9/L or platelet transfusion dependence, absolute neutrophil count \<1.5x10\^9/L. Erythroid response: Major-\>20g/L increase in hemoglobin or transfusion independence. Minor- 10-20g/L increase in hemoglobin or \>=50% decrease in transfusion requirements. Platelet response: Major-absolute increase of platelet count by \>=30x10\^9/L or platelet transfusion independence. Minor-\>=50% increase in platelet count with net increase \>10x10\^9/L but \<30x10\^9/L. (continued in Population Description)

Time frame:
Day 1 (randomization) to 6 months
Reported as:
Number · participants
Number of Participants With Best Hematological Improvement Derived Using International Working Group 2000 (IWG 2000) Criteria for MDS During the Initial Study Period.
participantsAza-5Aza-5-2-2Aza-5-2-5
Any Improvement n=50,49,47292026
Erythroid response - Major n=44,43,41181518
Erythroid response - Minor n=44,43,41412
Platelet response - Major n=24,28,28101110
Platelet response - Minor n=24,28,28200
Neutrophil response - Major n=24,22,16433
Neutrophil response - Minor n=24,22,16200
PrimaryNumber of Participants With Overall Best Hematologic Response and Hematologic Improvement Based on IWG 2000 Criteria For MDS During the Initial Study Period

Number of participants whose best hematological outcome was either complete remission (CR), partial remission (PR) (as determined by the investigator), or any hematologic improvement (based on the IWG 2000 criteria for MDS). See previous outcomes for detailed definitions.

Time frame:
Day 1 (randomization) to 6 months
Reported as:
Number · participants
Number of Participants With Overall Best Hematologic Response and Hematologic Improvement Based on IWG 2000 Criteria For MDS During the Initial Study Period
participantsAza-5Aza-5-2-2Aza-5-2-5
Number of Participants With Overall Best Hematologic Response and Hematologic Improvement Based on IWG 2000 Criteria For MDS During the Initial Study Period302027
SecondaryBaseline Hemoglobin Values

The median values for hemoglobin based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for hemoglobin. Baseline values are used to compare to values following treatment.

Time frame:
Day 1 (randomization)
Reported as:
Median · g/L
Baseline Hemoglobin Values
g/LAza-5Aza-5-2-2Aza-5-2-5
Baseline Hemoglobin Values94.0 (63.0 to 131.0)98.0 (70.0 to 135.0)95.5 (59.0 to 145.0)
SecondaryChange From Baseline in Hemoglobin at End of Initial Study Period (6 Months)

The difference between hemoglobin values at the end of the initial study period minus the hemoglobin values at baseline.

Time frame:
6 months
Reported as:
Median · g/L
Change From Baseline in Hemoglobin at End of Initial Study Period (6 Months)
g/LAza-5Aza-5-2-2Aza-5-2-5
Change From Baseline in Hemoglobin at End of Initial Study Period (6 Months)2.3 (-25.9 to 41.8)2.9 (-33.0 to 31.7)5.3 (-20.4 to 30.4)
PrimaryNumber of Participants Who Improved or Maintained The Hematologic Response From the Initial Study Period (Based on IWG 2000 Criteria For MDS) During the Maintenance Period

Hematologic response during the maintenance period are compared to the response in the initial study period. Initial response could have been a complete remission, a partial remission, stable disease or a hematologic improvement. Maintenance period best response is after randomization to a maintenance arm for those randomized, and is after the start of cycle 7 for those remaining on initial period treatment throughout the study.

Time frame:
24 months
Reported as:
Number · participants
Number of Participants Who Improved or Maintained The Hematologic Response From the Initial Study Period (Based on IWG 2000 Criteria For MDS) During the Maintenance Period
participantsMaintenance Aza 5 Days q 4 WeeksMaintenance Aza 5 Days q 6 WeeksInitial Period Treatment Continued Into Maintenance
Improved response from initial study period71012
Maintained response from initial study period6510
SecondaryChange From Baseline in Hemoglobin at the End of the Maintenance Study Period

The difference between hemoglobin values at the end of the maintenance study period minus the hemoglobin values at baseline.

Time frame:
24 months
Reported as:
Median · g/L
Change From Baseline in Hemoglobin at the End of the Maintenance Study Period
g/LMaintenance Aza 5 Days q 4 WeeksMaintenance Aza 5 Days q 6 WeeksInitial Period Treatment Continued Into Maintenance
Change From Baseline in Hemoglobin at the End of the Maintenance Study Period5.9 (-27.9 to 54.8)7.3 (-14.4 to 55.5)14.5 (-5.5 to 60.4)
SecondaryBaseline Platelet Values

The median values for platelets based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for platelets. Baseline values are used to compare to values following treatment.

Time frame:
Day 1 (randomization)
Reported as:
Median · x10(9)/L
Baseline Platelet Values
x10(9)/LAza-5Aza-5-2-2Aza-5-2-5
Baseline Platelet Values110.0 (9.0 to 516.0)90.0 (8.0 to 581.0)86.0 (8.0 to 699.0)
SecondaryChange From Baseline in Platelets at the End of Initial Study Period (6 Months)

The difference between platelet values at the end of the initial study period minus the platelet values at baseline.

Time frame:
6 months
Reported as:
Median · x10^9/L
Change From Baseline in Platelets at the End of Initial Study Period (6 Months)
x10^9/LAza-5Aza-5-2-2Aza-5-2-5
Change From Baseline in Platelets at the End of Initial Study Period (6 Months)4.8 (-116.3 to 179.1)5.7 (-145.6 to 192.6)12.6 (-300.9 to 213.6)
SecondaryChange From Baseline in Platelets at the End of the Maintenance Study Period (Month 24)

The difference between platelet values at the end of the maintenance study period minus the platelet values at baseline.

Time frame:
24 months
Reported as:
Median · x10^9/L
Change From Baseline in Platelets at the End of the Maintenance Study Period (Month 24)
x10^9/LMaintenance Aza 5 Days q 4 WeeksMaintenance Aza 5 Days q 6 WeeksInitial Period Treatment Continued Into Maintenance
Change From Baseline in Platelets at the End of the Maintenance Study Period (Month 24)19.8 (-157.5 to 129.6)7.7 (-279.8 to 166.3)17.3 (-124.7 to 223.3)
SecondaryBaseline Absolute Neutrophil Count (ANC) Values

The median values for ANC based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for ANC. Baseline values are used to compare to values following treatment.

Time frame:
Day 1 (randomization)
Reported as:
Median · x10^9/L
Baseline Absolute Neutrophil Count (ANC) Values
x10^9/LAza-5Aza-5-2-2Aza-5-2-5
Baseline Absolute Neutrophil Count (ANC) Values1.6 (0.1 to 13.9)1.9 (0.1 to 162.3)2.3 (0.3 to 139.3)
SecondaryChange From Baseline in Absolute Neutrophil Count (ANC) at the End of Initial Study Period (6 Months)

The difference between ANC values at the end of the initial study period minus the ANC values at baseline.

Time frame:
6 months
Reported as:
Median · x10^9/L
Change From Baseline in Absolute Neutrophil Count (ANC) at the End of Initial Study Period (6 Months)
x10^9/LAza-5Aza-5-2-2Aza-5-2-5
Change From Baseline in Absolute Neutrophil Count (ANC) at the End of Initial Study Period (6 Months)-0.3 (-4.6 to 1.9)-0.3 (-35.9 to 1.4)-0.4 (-9.7 to 8.5)
SecondaryChange From Baseline in Absolute Neutrophil Count (ANC) at the End of the Maintenance Study Period (Month 24)

The difference between ANC values at the end of the maintenance study period minus the ANC values at baseline.

Time frame:
24 months
Reported as:
Median · x10^9/L
Change From Baseline in Absolute Neutrophil Count (ANC) at the End of the Maintenance Study Period (Month 24)
x10^9/LMaintenance Aza 5 Days q 4 WeeksMaintenance Aza 5 Days q 6 WeeksInitial Period Treatment Continued Into Maintenance
Change From Baseline in Absolute Neutrophil Count (ANC) at the End of the Maintenance Study Period (Month 24)-0.1 (-17.6 to 2.0)-0.2 (-3.1 to 1.9)-0.4 (-19.0 to 2.3)
SecondaryRed Blood Cell (RBC) Transfusion Status at Baseline and End of Initial Study Period (6 Months)

Shift table comparing the RBC transfusion status of patients at the end of the initial study period to the transfusion status at baseline.

Time frame:
6 months
Reported as:
Number · participants
Red Blood Cell (RBC) Transfusion Status at Baseline and End of Initial Study Period (6 Months)
participantsAza-5Aza-5-2-2Aza-5-2-5
Baseline Dependent(n=25,24,22) - 6 mo Independent161413
Baseline Dependent(n=25,24,22) - 6 mo Dependent9109
Baseline Independent(n=25,26,29)- 6 mo Independent191619
Baseline Independent(n=25,26,29) - 6 mo Dependent61010
SecondaryPlatelet Transfusion Status at Baseline and End of Initial Study Period (6 Months)

Shift table comparing the platelet transfusion status of patients at the end of the initial study period to the transfusion status at baseline.

Time frame:
6 months
Reported as:
Number · participants
Platelet Transfusion Status at Baseline and End of Initial Study Period (6 Months)
participantsAza-5Aza-5-2-2Aza-5-2-5
Baseline Dependent (n=4,2,1) - 6 mo Independent320
Baseline Dependent (n=4,2,1) - 6 mo Dependent101
Baseline Independent(n=46,48,50)- 6 mo Independent434241
Baseline Independent (n=46,48,50) - 6 mo Dependent369
SecondaryRed Blood Cell (RBC) Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)

Shift table comparing the RBC transfusion status of patients at the end of the maintenance study period to the transfusion status at baseline.

Time frame:
24 months
Reported as:
Number · participants
Red Blood Cell (RBC) Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)
participantsMaintenance Aza 5 Days q 4 WeeksMaintenance Aza 5 Days q 6 WeeksInitial Period Treatment Continued Into Maintenance
Baseline Dependent (n=6,12,12) - 24 mo Independent51210
Baseline Dependent (n=6,12,12) - 24 mo Dependent102
Baseline Independent(n=16,9,15)- 24 mo Independent15915
Baseline Independent (n=16,9,15) - 24 mo Dependent100
SecondaryPlatelet Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)

Shift table comparing the platelet transfusion status of patients at the end of the maintenance study period to the transfusion status at baseline.

Time frame:
24 months
Reported as:
Number · participants
Platelet Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)
participantsMaintenance Aza 5 Days q 4 WeeksMaintenance Aza 5 Days q 6 WeeksInitial Period Treatment Continued Into Maintenance
Baseline Dependent (n=1,1,2) - 24 mo Independent112
Baseline Dependent (n=1,1,2) - 24 mo Dependent000
Baseline Independent(n=21,20,25)-24 mo Independent212025
Baseline Independent(n=21,20,25) - 24 mo Dependent000
SecondaryChange From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Initial Study Period

Baseline uses the average number of infections requiring IV antibiotic treatment from the 28 days prior to and including the day of first dose to an initial treatment arm. Initial study period values total the number of infections requiring IV antibiotic treatment divided by the number of treatment cycles (each cycle is approximately one month).

Time frame:
6 months
Reported as:
Median · infections per cycle
Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Initial Study Period
infections per cycleAza-5Aza-5-2-2Aza-5-2-5
Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Initial Study Period0.00 (0.00 to 1.00)0.00 (0.00 to 1.00)0.00 (-0.89 to 7.00)
SecondaryChange From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Maintenance Study Period

Baseline uses the average number of infections requiring IV antibiotic treatment from the 28 days prior to and including the day of first dose to an initial treatment arm. Maintenance study period values total the number of infections requiring IV antibiotic treatment divided by the number of treatment cycles (each cycle is approximately one month).

Time frame:
24 months
Reported as:
Median · infections per cycle
Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Maintenance Study Period
infections per cycleMaintenance Aza 5 Days q 4 WeeksMaintenance Aza 5 Days q 6 WeeksInitial Period Treatment Continued Into Maintenance
Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Maintenance Study Period0.00 (-1.00 to 0.00)0.00 (0.00 to 0.20)0.00 (0.00 to 0.67)

Adverse events

Collected over The 3 groups in the Initial Period cover Day 1-6 months, and up to 24 months for participants that continued that treatment. The 2 Maintenance Period groups cover months 7-24 for subjects who were randomized to 1 of the 2 Maintenance treatment arms.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aza-5—18/50 (36%)49/50 (98%)
Aza-5-2-2—27/50 (54%)50/50 (100%)
Aza-5-2-5—22/48 (45.8%)46/48 (95.8%)
Maintenance Aza 5 Days q 4 Weeks—7/22 (31.8%)18/22 (81.8%)
Maintenance Aza 5 Days q 6 Weeks—13/21 (61.9%)18/21 (85.7%)
Most frequent serious events
Showing 10 of 103
Most frequent serious events
EventAza-5Aza-5-2-2Aza-5-2-5Maintenance Aza 5 Days q 4 WeeksMaintenance Aza 5 Days q 6 Weeks
AnaemiaBlood and lymphatic system disorders2/505/501/480/223/21
PneumoniaInfections and infestations1/501/505/480/221/21
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/504/500/482/221/21
Myelodysplastic syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/500/501/482/221/21
Urinary tract infectionInfections and infestations0/500/504/480/220/21
Febrile neutropeniaBlood and lymphatic system disorders4/502/503/480/220/21
PancytopeniaBlood and lymphatic system disorders0/500/500/480/221/21
Angina pectorisCardiac disorders0/501/501/480/221/21
Cardiac failure congestiveCardiac disorders0/502/502/480/221/21
Myocardial infarctionCardiac disorders0/501/500/481/221/21
Most frequent other events
Showing 10 of 99
Most frequent other events
EventAza-5Aza-5-2-2Aza-5-2-5Maintenance Aza 5 Days q 4 WeeksMaintenance Aza 5 Days q 6 Weeks
NauseaGastrointestinal disorders31/5031/5023/482/226/21
FatigueGeneral disorders25/5030/5029/485/223/21
ConstipationGastrointestinal disorders28/5025/5021/482/222/21
Injection site erythemaGeneral disorders28/5028/5026/481/223/21
NeutropeniaBlood and lymphatic system disorders15/5022/5017/482/222/21
Injection site painGeneral disorders15/5018/5018/481/223/21
VomitingGastrointestinal disorders18/5012/5013/481/222/21
AnaemiaBlood and lymphatic system disorders11/5017/5012/483/225/21
DyspnoeaRespiratory, thoracic and mediastinal disorders17/5011/509/480/222/21
Oedema peripheralGeneral disorders4/5014/5016/483/223/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)Aza-5Aza-5-2-2Aza-5-2-5Total
Median76.0 (47 to 93)73.0 (37 to 88)76.0 (54 to 91)75.0 (37 to 93)
Sex: Female, Male
Sex: Female, Male(Participants)Aza-5Aza-5-2-2Aza-5-2-5Total
Female17221453
Male33283798
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aza-5Aza-5-2-2Aza-5-2-5Total
Caucasian474148136
Black or African American0426
Asian/Oriental1001
Hispanic2518
Other0000
ECOG Performance Status
ECOG Performance Status(Participants)Aza-5Aza-5-2-2Aza-5-2-5Total
0=Fully active12191445
1=Restricted32232984
2=Ambulatory/capable of self care35715
3=Capable/limited care3317
FAB Classification
FAB Classification(Participants)Aza-5Aza-5-2-2Aza-5-2-5Total
RA22222165
RARS77721
RAEB14141745
RAEB-T2114
CMMoL with <5% blasts3317
CMMoL with >=5% blasts2114
CMMoL with missing blasts0235
AML0000
Other0000
Transfusion Dependence - Platelets
Transfusion Dependence - Platelets(Participants)Aza-5Aza-5-2-2Aza-5-2-5Total
Platelet transfusion dependent4217
Not platelet transfusion dependent464850144
Transfusion Dependence Status - RBCs
Transfusion Dependence Status - RBCs(Participants)Aza-5Aza-5-2-2Aza-5-2-5Total
RBC transfusion dependent25242271
Not RBC transfusion dependent25262980
08

Study locations

31 sites
  • Comprehensive Blood and Cancer Center, Research Department
    Bakersfield, California 93309, United States
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211, United States
  • Cancer Center of Colorado Springs, The Oncology Clinic, PC
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Cancer Centers, LLP
    Denver, Colorado 80218, United States
  • Washington Cancer Institute
    Washington, District of Columbia 20010, United States
  • Florida Cancer Institute
    New Port Richey, Florida 34652, United States
  • Cancer Centers of Florida, P.A.
    Ocoee, Florida 34761, United States
  • Joliet Oncology-Hematology Associates, Ltd.
    Joliet, Illinois 60435, United States
  • Oncology/Hematology Associates of Central Illinois, PC
    Peoria, Illinois 61615-7828, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Hematology & Oncology Specialists LLC
    Metairie, Louisiana 70115, United States
  • Great Lakes Cancer Institute Breslin Cancer Center
    Lansing, Michigan 48910, United States
  • The Center for Cancer Care and Research
    Saint Louis, Missouri 63141, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Greater Dayton Cancer Center
    Kettering, Ohio 45409, United States
  • Western Pennsylvania Cancer Institute
    Pittsburgh, Pennsylvania 15224, United States
  • Oncology Services of Aberdeen
    Aberdeen, South Dakota 57401, United States
  • Avera Cancer Institute Leukemia-Bone Marrow Transplant Center
    Sioux Falls, South Dakota 57105, United States
  • McLeod Cancer and Blood Center
    Johnson City, Tennessee 37604, United States
  • The Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Texas Oncology, P.A.
    Bedford, Texas 76022, United States
  • Texas Cancer Center at Medical City
    Dallas, Texas 75230, United States
  • Texas Oncology, PA
    Fort Worth, Texas 76104, United States
  • San Antonio Tumor & Blood Clinic
    Fredericksburg, Texas 78624, United States
  • Cancer Care Centers of South Texas - HOAST
    San Antonio, Texas 78229, United States
  • Virginia Oncology Associates - Lake Wright Cancer Center
    Norfolk, Virginia 23502, United States
  • Highline Medical Oncology
    Burien, Washington 98166, United States
  • Puget Sound Cancer Center
    Edmonds, Washington 98026, United States
  • Puget Sound Cancer Center
    Seattle, Washington 98133, United States
  • Cancer Care Northwest
    Spokane, Washington 99218, United States
  • Northwest Cancer Specialists, P.C.
    Vancouver, Washington 98684, United States
09

References and documents

Publications

  • R. Lyons, et al. Rapid onset of effectiveness with three alternative azacitidine (aza) dosing regimens in patients (pts) with myelodysplastic syndromes (MDS). Haematologica 2008;93(suppl 1):Abs.0232.
  • Lyons R, et al. Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. Presented at the 2007 ASCO Annual Meeting, June 1-5, 2007, Chicago, IL. Abstract No. 7083
  • Komrokji R, Swern AS, Grinblatt D, Lyons RM, Tobiasson M, Silverman LR, Sayar H, Vij R, Fliss A, Tu N, Sugrue MM. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies. Oncologist. 2018 Feb;23(2):159-170. doi: 10.1634/theoncologist.2017-0215. Epub 2017 Nov 8. PubMed 29118268 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2005 to primary completion in Aug 2008, 43 months.

Results were first posted in May 2010, 1 year 9 months after primary completion.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 43 months is close to that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2005
First posted
Feb 1, 2005
StartActual
Jan 1, 2005
Primary completionActual
Aug 1, 2008
CompletionActual
Aug 1, 2008
Results first posted
May 28, 2010
Last update
Nov 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00102687
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Feb 1, 2005
Start date
Jan 1, 2005
Primary completion
Aug 1, 2008
Completion
Aug 1, 2008
Results posted
May 28, 2010
Last update
Nov 22, 2019

Study contacts

CL Beach
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion